Provided by Tiger Trade Technology Pte. Ltd.

Edwards Lifesciences

85.21
+0.97001.15%
Post-market: 85.260.0500+0.06%19:38 EDT
Volume:3.89M
Turnover:328.51M
Market Cap:49.13B
PE:49.57
High:85.34
Open:84.60
Low:83.22
Close:84.24
52wk High:96.29
52wk Low:72.30
Shares:576.54M
Float Shares:575.03M
Volume Ratio:1.02
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.72
EPS(LYR):1.83
ROE:9.18%
ROA:8.37%
PB:4.63
PE(LYR):46.49

Loading ...

Edwards Lifesciences CVP, TAVR Daniel J. Lippis Disposes of 619 Common Shares for $53,017.35

Reuters
·
Yesterday

Edwards Lifesciences Corp. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Yesterday

Edwards Lifesciences Price Target Announced at $110.00/Share by Barclays

Dow Jones
·
Oct 07

Press Release: Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

Dow Jones
·
Oct 07

Barclays Remains a Buy on Edwards Lifesciences (EW)

TIPRANKS
·
Oct 07

Edwards Lifesciences initiated with an Overweight at Barclays

TIPRANKS
·
Oct 07

Edwards Lifesciences Corp. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Oct 06

Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating

MT Newswires Live
·
Oct 05

Edwards Lifesciences to Host Investor Event Alongside TCT Symposium Webcast

Reuters
·
Oct 05

Edwards Lifesciences (EW) Receives a Buy from RBC Capital

TIPRANKS
·
Oct 03

Edwards Lifesciences Receives FDA Approval for Autus Valve, the First Surgical Pulmonary Valve for Pediatric Patients

THOMSON REUTERS
·
Oct 02

US FDA - Approves Autus Size-Adjustable Valve for Pediatric Congenital Pulmonary Valve Disease

THOMSON REUTERS
·
Oct 02

US FDA - Edwards Lifesciences Receives FDA Approval for Autus Size-Adjustable Valve

THOMSON REUTERS
·
Oct 02

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 01

Edwards Lifesciences' TAVR Evaluation in Moderate Aortic Stenosis Among Most Awaited Clinical Trial Readouts, Oppenheimer Says

MT Newswires Live
·
Sep 30

Leerink Partners Sticks to Their Buy Rating for Edwards Lifesciences (EW)

TIPRANKS
·
Sep 29

Edwards Lifesciences Corp. Stock Advances 4.1%, Outperforms Peers

Dow Jones
·
Sep 17

Movement Alert|Edwards Lifesciences Rises 3.08% in Regular Trading, Medicare TAVR Coverage Decision and Guidance Reaffirmation Boost Sentiment

Market Focus
·
Sep 16

Edwards Lifesciences CVP, TAVR Daniel J. Lippis Disposes of 619 Common Shares Worth $54,168.69

Reuters
·
Sep 12

Edwards Lifesciences Corp. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 12